BWXT Insider Filing: Gerhard Burbach Reports 19.4 DERs, Ownership 723.65 Shares
Rhea-AI Filing Summary
Gerhard F. Burbach, a director of BWX Technologies, Inc. (BWXT), reported a Section 16 transaction dated 09/05/2025. The filing shows the accrual and acquisition of 19.4 dividend equivalent rights related to six restricted stock unit (RSU) grants for which the reporting person elected to defer receipt of the underlying shares. Each RSU and dividend equivalent right (DER) represents a contingent right to one share of BWXT common stock. The DERs have a reported price of $0 and, per the deferral election, will be delivered proportionately with the related RSUs. The filing lists 723.65 shares as the amount beneficially owned following the reported transaction. The form is signed on behalf of Mr. Burbach by an attorney-in-fact.
Positive
- Director Gerhard F. Burbach reported acquisition of 19.4 dividend equivalent rights
- Filing discloses beneficial ownership post-transaction as 723.65 shares
- Transaction arises from an existing RSU deferral election, consistent with equity compensation practices
Negative
- None.
Insights
TL;DR: Routine insider deferral resulted in 19.4 dividend-equivalent rights, increasing disclosed beneficial ownership to 723.65 shares.
This Form 4 documents a non-cash, administrative accrual tied to pre-existing restricted stock unit awards rather than an open-market purchase or sale. The 19.4 dividend equivalent rights represent contingent claims to common shares and carry a reported price of $0, consistent with dividend equivalent accounting and deferral elections. The filing increases the disclosed beneficial ownership to 723.65 shares, providing transparency on the director's holdings but reflecting a small incremental change relative to typical institutional positions.
TL;DR: Disclosure is compliant and describes a deferral election delivering DERs with RSUs; no indication of new cash consideration or policy change.
The report clearly states the nature of the instrument (DERs tied to six RSU grants) and the mechanism (deferral election). Signature by an attorney-in-fact is properly indicated. This is a routine, internal compensation-related transaction that aligns with typical board-member equity deferral practices and does not, on its face, indicate any governance or trading-policy issues.